The BPC-157 + TB-500 combination, the most-talked-about peptide stack for tissue repair. Named for the X-Men character with accelerated healing. Uses two peptides researchers have studied separately, never together.
The 30-second read
The WOLVERINE blend is a pre-mixed combination of BPC-157 and TB-500, two peptides that researchers have separately studied for tissue repair in animals. The pitch: BPC-157 is associated with growth factor and blood-vessel signaling, TB-500 with cell migration, different parts of the same healing process, theoretically complementary. The reality: there are zero published human studies of this specific combination. Each peptide individually has decades of preclinical research and very limited human evidence. The Wolverine framing came from podcasters and athletes, not from clinicians or researchers. It's not FDA-approved. Both component peptides are on the FDA's Category 2 list. Worth understanding what each component actually is, links above.
Why this blend is on people's radar
The Wolverine name caught on for an obvious reason: in X-Men, Wolverine has a regenerative ability that makes injuries heal almost as fast as they happen. That's exactly what people with stubborn tendinitis, partial muscle tears, or tendon injuries want. Joe Rogan helped popularize the BPC-157 + TB-500 combination on his podcast, and athletes recovering from significant injuries, including Jeremy Renner after the 2023 snowplow accident, have publicly named both peptides as part of their recovery protocols.
The mechanistic logic for combining the two is reasonable on paper. BPC-157 has been studied for promoting new blood vessel formation and growth-factor expression in injured tissue (tendons, gut, muscle). TB-500 (a fragment of Thymosin Beta-4) has been studied for cell migration, getting the cells that need to be at the injury site to actually move there. Different parts of the same healing process. The argument: combining them might cover more of the recovery cascade than either alone.
What's missing: a single human clinical trial of the specific combination. All the published evidence is on the individual peptides, almost entirely from animal studies. The "Wolverine" framing came from popular culture, not from clinicians or researchers. The April 2026 FDA Pharmacy Compounding Advisory Committee review of seven compounded peptides included both BPC-157 and TB-500 in scope, that's the regulatory context for this entire conversation.
What people are usually trying to do with it
People exploring the Wolverine blend are typically focused on:
A stubborn tendinitis or partial tendon injury that hasn't healed with rest
Recovery from a muscle tear or pull that's lingering
Joint inflammation that keeps flaring up
Bouncing back from surgery or a major training event
Generally getting back to "feeling normal" after a series of injuries
What the science actually shows
Plain-English summary, with the most important caveat first:
No human trials of the blend
There are zero published human clinical trials of the specific BPC-157 + TB-500 combination. Anything anyone says about the blend's effectiveness is extrapolated from individual-peptide research and from anecdote.1
BPC-157 individual research
Over a thousand published preclinical studies; about three small human pilot studies, all from one Florida research group. Animal evidence is strongest for tendon, gut, and muscle repair. Full BPC-157 explainer →
TB-500 individual research
Decades of Thymosin Beta-4 research with consistent animal data on wound healing and cell migration. The actual TB-500 fragment used in research-peptide products has thinner clinical evidence than the parent protein. Full TB-500 explainer →
Mechanistic complementarity (theoretical)
The case for combining them rests on the two peptides addressing different parts of the healing cascade, angiogenesis and growth-factor signaling (BPC-157) plus cell migration (TB-500). This is plausible biology. It is not the same as proven synergy in humans.2
What the blend has not been shown to do
Reliably heal any specific human injury in a controlled trial. Outperform either peptide alone in any human study (because no head-to-head comparisons exist). Replace physical therapy or other proven recovery interventions.
The honest read
What's solid:
Each individual peptide has decades of preclinical research with consistent animal data on tissue repair. The mechanistic complementarity argument for combining them has reasonable biological logic. The reported tolerability of both peptides individually has been generally favorable in the small available human evidence base.
What's still unproven:
Effectively everything about the specific combination in humans. There are no clinical trials of the blend. There are no head-to-head studies against either peptide alone. Long-term safety data on the combination doesn't exist. The "Wolverine" effect is reported anecdotally by podcasters and patients, not measured in trials.
What's hyped beyond the evidence:
Treating the Wolverine blend as a clinically established tissue-repair stack. It isn't. The naming and framing came from popular culture. People who report dramatic results are usually doing serious physical therapy alongside, which makes the contribution of any peptide hard to isolate. People doing the same physical therapy without peptides also often report meaningful improvements.
Things to know if you're looking into it
Two peptides, one vial: the WOLVERINE blend is typically a pre-mixed product containing BPC-157 and TB-500 in a single vial, dosed together. Some research-peptide protocols use them as separate injections instead.
Frequency: typical research-community protocols dose BPC-157 daily and TB-500 less frequently (one or two times per week), reflecting their different half-lives. Pre-mixed blends usually compromise on a daily-dosing schedule.
Regulatory status: not FDA-approved. Both components are on the FDA's Category 2 list as of September 2023, making them ineligible for licensed-pharmacy compounding under standard pathways. The April 2026 FDA advisory panel review included both in scope.
Athlete bans: both BPC-157 and TB-500 are on the World Anti-Doping Agency banned list. Competitive athletes will test positive.
Pairs with rehab, not in place of it: the strongest reports of benefit come from people doing aggressive physical therapy alongside. The peptide is at most an adjunct to a real rehab program.
Healthcare provider involvement: a licensed clinician should be part of any decision about use, especially for serious injuries that warrant proper diagnosis first.
Component breakdowns: see the dedicated BPC-157 and TB-500 pages for full mechanism, dosing, and reference detail. The "Want to go deeper?" section below summarizes the blend-specific considerations.
Reconstitution & dose calculator
1:1 BPC-157 + TB-500 blend. Zero published human studies on the specific combination. Both components are on the FDA Category 2 list (Sept 2023). The dose math below uses combined peptide mass — a 500 mcg dose means 250 mcg of BPC-157 plus 250 mcg of TB-500. Compounded blend quality varies. WADA and most pro/collegiate sports lists ban both peptides. This is an educational reference, not dosing guidance.
Suggested start
250 mcg/inj
125 mcg of each peptide
Common range
500–1000 mcg/inj
250–500 mcg of each peptide
Max dose
1000 mcg/inj
500 mcg of each — community ceiling
Cycle
4–8 wks on
Then 2–4 weeks off
mL
Defaults to a 5 mg/mL combined dilution — standard 500 mcg dose lands at a clean 10 units, 1000 mcg at 20 units. The 5/5 vial uses 2 mL water; the 10/10 uses 4 mL. If your vial can't hold 4 mL, drop to 2 mL on the 10/10 (10 mg/mL combined, half the syringe units).
mcg
Subcutaneous injection, typically once daily. The number above is the combined peptide mass — split evenly between BPC-157 and TB-500. A 500 mcg dose = 250 mcg BPC + 250 mcg TB.
Above the typical community range. Combined per-injection doses above 1000 mcg (500 mcg each peptide) push BPC-157 past its pilot-study ceiling and accelerate the TB-500 weekly load. There's no human data above this combined range.
Concentration
5.0 mg/mL
Per dose
0.10 mL
10 units on insulin syringe
Doses per vial
~40
~40 days (~5.7 weeks) of daily dosing
When to stay put vs. adjust
Stay put at 500 mcg combined daily when the injury or issue is showing improvement, even slowly — tendon and connective tissue work on weeks-to-months timelines, not days. Effects on chronic gut inflammation tend to register sooner. Either way, don't escalate just because results aren't dramatic in week one.
Consider stepping to 1000 mcg combined daily only after at least four weeks at 500 mcg with clear tolerability and limited progress on the issue you're tracking. Above this combined range, you exit pilot-study territory for both peptides simultaneously, and there's no human data to anchor to.
The frequency mismatch is real and unresolved. BPC-157 is normally daily; TB-500 is normally 1–2× weekly because of half-life differences. A pre-mixed blend forces both onto the same schedule — usually daily. Some users prefer to dose Wolverine 3–4× weekly instead to better match TB-500's natural cadence; others stay daily and accept the mismatch. There's no clinical data showing which approach is better. If you want the cleanest individual-peptide dosing, use BPC-157 and TB-500 as separate injections rather than a blend.
Cycle off at the 4–8 week mark regardless of progress. Long-term continuous use of either peptide isn't characterized in humans, much less the combination. The 2–4 week off period is community wisdom rather than evidence-based, but it errs on the side of caution.
Pair with rehab, not in place of it. The strongest community reports of benefit come from people doing aggressive physical therapy or progressive loading alongside. The peptide blend is at most an adjunct to a real rehab program — substituting it for proper rehabilitation is the most reliable way to be disappointed in the result.
The honest read. There are zero published human trials of the specific BPC + TB combination. The mechanistic case for combining them is reasonable on paper (different parts of the same healing cascade), but reasonable-on-paper isn't evidence. Each peptide individually has thin human data; the blend has even less. Compounded blend quality varies meaningfully — the actual peptide content can differ from the label.
For educational and research purposes only. This is not medical advice. Both BPC-157 and TB-500 are not FDA-approved and are on the FDA Category 2 list (Sept 2023). Both are on WADA and most pro/collegiate sports prohibited-substance lists. Compounded blends operate outside FDA drug oversight. Consult a licensed healthcare provider before any health decision.
What people often ask
Is the WOLVERINE blend better than either peptide alone?
There are no head-to-head studies. The argument for the combination is mechanistic, that the two peptides address different parts of the healing process. Whether that translates into better real-world results than either alone is anecdotal at best.
Why is it called "WOLVERINE"?
The name was popularized in podcast and biohacking culture and refers to the X-Men character with accelerated healing. It's a marketing-and-community label, not a scientific one. There's no formal medical name for the BPC-157 + TB-500 combination.
How is it usually used?
Most pre-mixed blend products are dosed as a daily subcutaneous injection over a 4 to 8 week course. Some research-community protocols use the two peptides separately at their individual frequencies (BPC-157 daily, TB-500 1–2x weekly).
Is it safe?
Each component has limited human safety data individually, and there's no safety data on the combination specifically. Reported side effects in research-community use are generally mild and uncommon. Long-term safety with continuous use isn't characterized.
Can I get it through a compounding pharmacy?
Both components are on the FDA's Category 2 list as of September 2023, making compounding by licensed pharmacies legally restricted. The April 2026 FDA panel review may change this; check the most current FDA status.
Will I test positive on a drug test?
Yes, both BPC-157 and TB-500 are on the World Anti-Doping Agency banned list and the NCAA's prohibited-substance list. Competitive athletes should not use the blend.
Should I expect dramatic results?
The honest answer is: probably not, and most reports of dramatic results involve people doing aggressive physical therapy alongside. The peptide story is at most an adjunct to a real recovery program.
FDA and regulatory status
⚡ Regulatory update. April 15, 2026
The FDA Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review whether BPC-157 and TB-500 (along with five other peptides) should be removed from the Category 2 list. Both are blend components. The panel's recommendation is advisory; the FDA retains final decision authority. Sources: FDA.gov, STAT News.
Status as of May 5, 2026: The WOLVERINE blend is not FDA-approved as a combined formulation. Both component peptides (BPC-157, TB-500) are individually on the FDA Category 2 list as of September 2023, making compounding-pharmacy access legally restricted. Both are on the WADA banned list. Status updates land here when they happen.
Notable commentary
The WOLVERINE framing came from popular culture. The same names that pulled BPC-157 and TB-500 into the mainstream conversation pulled the blend along with them.
Joe Rogan and the "Wolverine stack"
The "Wolverine stack" framing for the BPC-157 + TB-500 combination has been pushed into mainstream awareness largely through repeated discussion on The Joe Rogan Experience. Mainstream coverage has noted his influence while flagging that human clinical evidence for either component remains limited.
Personal anecdote and media commentary, not clinical evidence. For educational purposes only.
Want to go deeper?
Component breakdowns, mechanism complementarity, blend dosing considerations, side effects, and references. Click to expand.
The two components, briefly
BPC-157, the angiogenesis and growth-factor side
A 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. Studied in animal models for tissue repair, particularly tendons and the gut lining. Roughly 1,000+ preclinical publications and ~3 small human pilot studies. Read the full BPC-157 explainer →
TB-500, the cell-migration side
A 17-amino-acid synthetic peptide corresponding to the active region of Thymosin Beta-4, a naturally occurring repair protein. Studied for cell migration during tissue repair. Decades of Thymosin Beta-4 preclinical research; thinner clinical evidence specifically for the synthetic fragment. Read the full TB-500 explainer →
Mechanism of the combination (theoretical)
The case for combining the two peptides is mechanistic complementarity:
The complementarity argument: BPC-157 helps build the supply lines (blood vessels, growth signals), TB-500 helps the right cells get to and reorganize at the injury site.
This is biological logic, not proven synergy in humans. Whether 1+1=3 (synergy), 1+1=2 (additive), or 1+1=1.5 (some redundancy) in humans hasn't been studied.
Commonly studied dosing of components
These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.
Pre-mixed blend products: typically combine BPC-157 (often 5–10 mg per vial) with TB-500 (often 5–10 mg per vial). Daily-dosing protocols compromise between the components' different half-lives.
Separate-dose research-community protocols: BPC-157 ~250 mcg daily plus TB-500 2–5 mg once or twice weekly. Reflects each peptide's individual pharmacology more closely.
Treatment duration: typical research-community cycle ranges are 4 to 8 weeks. Long-term continuous use has not been characterized for safety.
Side effects and safety considerations
Reported in research-community use of either component, individually or as a blend:
Mild injection-site redness or tenderness
Transient lethargy or "flu-like" feeling shortly after dose
Mild nausea (occasional)
Mild headache (uncommon)
Theoretical concerns: any peptide that promotes angiogenesis carries theoretical concerns about effects on tumor biology. There are no reports of either component promoting tumor growth, but the question has not been adequately studied. Long-term safety in healthy adults using continuous blends is not characterized.
References
PubMed search of "BPC-157 + TB-500" or "BPC-157 + Thymosin Beta-4" combinations: no published human clinical trials of the combination identified as of May 2026. PubMed
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012). "Thymosin β4: a multi-functional regenerative peptide." Expert Opin Biol Ther, 12(1), 37–51. PubMed
Staresinic M, Sikiric P, Anic T, et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon." J Orthop Res, 21(2), 976–983. PubMed
Malinda KM, Sidhu GS, Mani H, et al. (1999). "Thymosin beta4 accelerates wound healing." J Invest Dermatol, 113(3), 364–368. PubMed
U.S. Food and Drug Administration. (2023). "Pharmacy Compounding Guidance. FDA Category 2 List." FDA.gov
For educational and research purposes only. This is not medical advice. The WOLVERINE blend is not FDA-approved as a combined formulation. Both component peptides (BPC-157, TB-500) are on the FDA's Category 2 list as of September 2023. There are no published human clinical trials of this combination. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.